SCHEMBL6777260

SCHEMBL6777260

Clc1cccc2ccc(N3CCNCC3)nc12

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR3E A5X5Y0 3/20 0.59
HTR3B O95264 3/20 0.59
HTR3A P46098 3/20 0.59
HTR3D Q70Z44 3/20 0.59
HTR3C Q8WXA8 3/20 0.59
ALDH1A1 P00352 2/20 0.59
ADRB1 P08588 4/20 0.58
HTR2C P28335 2/20 0.58
SLC6A4 P31645 2/20 0.58
KDM4E B2RXH2 2/20 0.58
CYP3A4 P08684 2/20 0.58
HSD17B10 Q99714 2/20 0.58
USP2 O75604 1/20 0.58
CYP1A2 P05177 1/20 0.58
HTR1A P08908 1/20 0.58
MAPK1 P28482 1/20 0.58
HTR7 P34969 1/20 0.58
HTT P42858 1/20 0.58
HTR6 P50406 1/20 0.58
PMP22 Q01453 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2423343 0.81 GAA (0.68) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL3299921 0.81 HTR3A (0.58) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL6767019 0.78 ADRB1 (0.54) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL6776065 0.77 HTR3A (0.60) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL24844858 0.76 LMNA (0.57) KDM4EHTTPDE10AGAA
SCHEMBL615260 0.75 HTR3E (1.00) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL6771995 0.75 PTPN11 (0.55) HTR3EHTR3BHTR3AHTR3DHTR3C
Quipazine SCHEMBL322181 0.73 KDM4E (1.00) HTR3EHTR3BHTR3AHTR3DHTR3C
Hydrochloric Acid SCHEMBL11600638 0.73 HTR3E (0.96) HTR3EHTR3BHTR3AHTR3DHTR3C
Quipazine SCHEMBL4062074 0.72 KDM4E (0.97) HTR3EHTR3BHTR3AHTR3DHTR3C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6821967-B2 AMINES SUCH AS 9-(4-(4-(BENZOTHIAZOL-2-YL)-PIPERAZIN-1-YL)-BUTYL)-9H-FLUORENE-9-CARBOXYLIC ACID (2,2,2-TRIFLUOROETHYL) AMIDE, USED AS MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN ANTAGONISTS, TO PREVENT ATHEROSCLEROSIS OR HYPERLIPEMIA BOEHRINGER INGELHEIM PHARMA KG (DE) 2004-11-23 US disclosed
US-20030166637-A1 Substituted piperazine derivatives, the preparation thereofand their use as medicaments BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2003-09-04 US disclosed
EP-1255736-A2 SUBSTITUTED PIPERAZINE DERIVATIVES AND THEIR USE AS INHIBITORS OF THE MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN (MTP) Boehringer Ingelheim Pharma KG (DE) 2002-11-13 EP disclosed
WO-2001047898-A2 SUBSTITUTED PIPERAZINE DERIVATIVES AND THEIR USE AS INHIBITORS OF THE MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN (MTP) BOEHRINGER INGELHEIM PHARMA KG (DE) 2001-07-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030166637-A1 Substituted piperazine derivatives, the preparation thereofand their use as medicaments MTTP, CETP, CPT1A HTR3E 3268/4885HTR3B 3245/4885HTR3A 2835/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.